15 articles for T Yamada
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography.

Yamanouchi Pharmaceutical
Design, synthesis, and properties of des-D-ring interphenylene derivatives of 1α,25-Dihydroxyvitamin D

Kanagawa University
Highly Potent and Oral Macrocyclic Peptides as a HIV-1 Protease Inhibitor: mRNA Display-Derived Hit-to-Lead Optimization.

Shionogi
Structure-activity relationship of N-[2-(dimethylamino)-6-[3-(5-methyl-4-phenyl-1H-imidazol-1-yl)propoxy] phenyl]-N'-pentylurea and analogues. Novel potent inhibitors of acyl-CoA:cholesterol O-acyltransferase with antiatherosclerotic activity.

Eisai
Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities.

University of Arizona
Novel 3alpha-methoxyserrat-14-en-21beta-ol (PJ-1) and 3beta-methoxyserrat-14-en-21beta-ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents.

Osaka University of Pharmaceutical Sciences
DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Cellarity
HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS

Merck Patent
Methods to determine KDM1A target engagement and chemoprobes useful therefor

Oryzon Genomics
Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine

Nektar Therapeutics
Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

Bristol-Myers Squibb
Adenosine receptor agonists, partial agonists, and antagonists

The United States of America, As Represented By The Secretary, Department of Health and Human Services
Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.

The Scripps Research Institute
2-styrylchromones as novel inhibitors of xanthine oxidase. A structure-activity study.

University of Porto-Rua Anibal Cunha
Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.

University of Occupational and Environmental Health